At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Serum Sample Collectionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury
In Brief
An observational study evaluating Serum Sample Collection for Traumatic Brain Injury. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study aims is to describe the pharmacokinetic properties of levetiracetam through measurement of serum concentrations in critically ill, severe traumatic brain injury patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTraumatic Brain Injury
CountriesUnited States
CollaboratorsAmerican College of Clinical Pharmacy
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedApr 2021
Primary CompletionMay 2022
Study CompletionOct 2023
TodayJul 2026
First PostedApr 8, 2021
Enrollment StartJan 1, 2021
Primary CompletionMay 1, 2022
Study CompletionOct 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.2 years ago
Interventions
Serum Sample Collectionother
Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.